Targeted therapy in head and neck cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Head and neck squamous cell carcinoma (HNSCC) incidence is increasing globally.
• Conventional therapies for advanced HNSCC often lead to treatment failure and significant toxicity.
• There is a critical need for alternative and more effective treatment strategies.

Purpose of the Study:

• To explore the potential of molecular targeted therapy in improving outcomes for HNSCC.
• To review current and emerging targeted agents and their mechanisms of action.
• To discuss the role of targeted therapy as a complement to conventional treatments.

Main Methods:

• Review of existing literature on molecular targeted therapies for HNSCC.
• Analysis of targeted agents including EGFR, VEGFR, and other pathway inhibitors.
• Examination of combination strategies with conventional therapies.

Main Results:

• Targeted therapies show promise in inhibiting tumor growth and metastasis by focusing on specific molecular pathways.
• Agents like EGFR inhibitors (e.g., Cetuximab) and VEGFR inhibitors (e.g., Bevacizumab) are being investigated.
• Combination of targeted therapy with conventional treatments may enhance efficacy and disease control without increased toxicity.

Conclusions:

• Molecular targeted therapy holds significant promise for HNSCC treatment, offering increased selectivity and potentially fewer side effects.
• While some targeted agents are in use, others require further investigation due to mixed results.
• Identifying predictive biomarkers for patient selection remains a crucial challenge for personalized HNSCC treatment.